Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly
Increasingly, clinical trials for Alzheimer’s disease (AD) are being conducted earlier in the disease phase and with biomarker confirmation using in vivo amyloid PET imaging or CSF tau and Aβ measures to quantify pathology. However, making such a pre-clinical AD diagnosis is relatively costly and th...
Autors principals: | Westwood, S, Leoni, E, Hye, A, Baird, A, Lovestone, S |
---|---|
Format: | Journal article |
Publicat: |
IOS Press
2016
|
Ítems similars
-
Plasma based markers of [11C] PiB-PET brain amyloid burden.
per: Steven John Kiddle, et al.
Publicat: (2012-01-01) -
Early-Phase 11C-PiB PET in Amyloid Angiopathy-Related Symptomatic Cerebral Hemorrhage: Potential Diagnostic Value?
per: Karim Farid, et al.
Publicat: (2015-01-01) -
MR-less surface-based amyloid assessment based on 11C PiB PET.
per: Luping Zhou, et al.
Publicat: (2014-01-01) -
PiB fails to map amyloid deposits in cerebral cortex of aged dogs with canine cognitive dysfunction
per: Rikke eFast, et al.
Publicat: (2013-12-01) -
Estimation of brain amyloid accumulation using deep learning in clinical [11C]PiB PET imaging
per: Claes Nøhr Ladefoged, et al.
Publicat: (2023-07-01)